Others titles
- New ATC Code 2022
- New ATC Update and Alterations
- New DDD Updates and Alterations
Keywords
- ATC Classification
- ATC/DDD
- ATC Alterations
- DDD Alterations
- New ATC
- New DDD
Anatomical Therapeutic Chemical Alterations 2005 to 2022

This dataset contains the ATC (Anatomical Therapeutic Chemical) Alterations from 2005 to 2022.
Get The Data
- Research
Non-Commercial,
Share-Alike,
Attribution Free Forever
- Commercial
Commercial Use,
Remix & Adapt,
White Label Log in to download
Description
Cumulative overview of all ATC (Anatomical Therapeutic Chemical) alterations performed in the period 2005 to 2018. The year changed is when the alterations were implemented in the ATC/DDD (Anatomical Therapeutic Chemical/Defined Daily Dose) Index. Active ingredients which fulfill one of the following criteria will normally be included in the ATC system. They are existing well defined chemical entities used in a variety of countries. In ATC the active substances are divided into different groups according to the organ or system on which they act and their therapeutic, pharmacological and chemical properties.
Drugs are classified in groups at five different levels. The drugs are divided into fourteen main groups (1st level), with pharmacological/therapeutic subgroups (2nd level). The 3rd and 4th levels are chemical/pharmacological/therapeutic subgroups and the 5th level is the chemical substance. The 2nd, 3rd and 4th levels are often used to identify pharmacological subgroups when that is considered more appropriate than therapeutic or chemical subgroups.
About this Dataset
Data Info
Date Created | 2005 |
---|---|
Last Modified | 2021-11-24 |
Version | 2021-11-24 |
Update Frequency |
Semiannual |
Temporal Coverage |
2005-2022 |
Spatial Coverage |
United States |
Source | John Snow Labs; WHO Collaborating Centre for Drug Statistics Methodology; |
Source License URL | |
Source License Requirements |
N/A |
Source Citation |
N/A |
Keywords | ATC Classification, ATC/DDD, ATC Alterations, DDD Alterations, New ATC, New DDD |
Other Titles | New ATC Code 2022, New ATC Update and Alterations, New DDD Updates and Alterations |
Data Fields
Name | Description | Type | Constraints |
---|---|---|---|
Previous_ATC_Code | Previous ATC Code | string | - |
Substance_Name | Substances Indicated for Rare Disorders with Individual Dosing | string | - |
New_ATC_Code | New or altered ATC (Anatomical Therapeutic Chemical) Code | string | - |
Year_Changed | Year when ATC Code was altered | date | - |
Other_ATC_Code | Other Anatomical Therapeutic Chemical Code | string | - |
Previous_ATC_Level_Name | Previous Name of ATC Level Anatomical Therapeutic Chemical | string | - |
New_ATC_Level_Name_or_New_ATC_Level | New or altered ATC (Anatomical Therapeutic Chemical) Name | string | - |
Data Preview
Previous ATC Code | Substance Name | New ATC Code | Year Changed | Other ATC Code | Previous ATC Level Name | New ATC Level Name or New ATC Level |
A03AE02 | tegaserod | A06AX06 | 2013 | A05AA | Bile acid preparations | Bile acids and derivatives |
A03AE04 | prucalopride | A06AX05 | 2013 | B02BD08 | eptacog alfa | coagulation factor VIIa |
A10BX04 | exenatide | A10BJ01 | 2017 | J01CR01 | ampicillin and enzyme inhibitor | ampicillin and beta-lactamase inhibitor |
A10BX07 | liraglutide | A10BJ02 | 2017 | J01CR02 | amoxicillin and enzyme inhibitor | amoxicillin and beta-lactamase inhibitor |
A10BX09 | dapagliflozin | A10BK01 | 2017 | J01CR03 | ticarcillin and enzyme inhibitor | ticarcillin and beta-lactamase inhibitor |
A10BX10 | lixisenatide | A10BJ03 | 2017 | J01CR05 | piperacillin and enzyme inhibitor | piperacillin and beta-lactamase inhibitor |
A10BX11 | canagliflozin | A10BK02 | 2017 | J01DD51 | cefotaxime, combinations | cefotaxime and beta-lactamase inhibitor |
A10BX12 | empagliflozin | A10BK03 | 2017 | J01DD52 | ceftazidime, combinations | ceftazidime and beta-lactamase inhibitor |
A10BX13 | albiglutide | A10BJ04 | 2017 | J01DD62 | cefoperazone, combinations | cefoperazone and beta-lactamase inhibitor |
A10BX14 | dulaglutide | A10BJ05 | 2017 | J01DH51 | imipenem and enzyme inhibitor | imipenem and cilastatin |